How The System Helps You Succeed
What’s Included in the System
How Implementation Works
Why A Structured System Matters
Real Practice Outcomes
Creating a Profitable Practice
Patient Demand 
Patient Education 
Staff Education 
Marketing 
Regenerative Medicine Platform
Franchise & PE Support 
Wharton’s Jelly
Exosomes
Anti-Aging
Aesthetic Treatments
Neurological
Autoimmune
Wound Care
Orthopedic Conditions
Clinical Trials
Articles
Research Institutes
NAD+ (Nicotinamide Adenine Dinucleotide) is a vital coenzyme found in every cell of the body. It plays a central role in energy metabolism, mitochondrial function, DNA repair, and cellular signaling. Levels of NAD+ decline with age, stress, and chronic illness, which has made it a focus of longevity and regenerative medicine research. In laboratory and clinical studies, NAD+ supplementation (through IV, injectable, or precursor compounds) is being investigated for its potential to improve cellular energy, support healthy aging, and protect against metabolic and neurodegenerative diseases. NAD+ in therapeutic or supplemental form remains experimental and is not FDA-approved for general medical use.
How It Is Used in Research Settings
- Studied for enhancing mitochondrial energy production and ATP generation.
- Explored in aging models for supporting DNA repair and sirtuin activation.
- Investigated for metabolic benefits in insulin resistance, type 2 diabetes, and obesity research.
- Examined in neurodegenerative disease models for potential neuroprotective effects (Alzheimer’s, Parkinson’s).
- Used in addiction research for potential support in recovery and detoxification studies.
Proposed Uses (Research Areas)
- Aging and longevity research.
- Metabolic health — insulin resistance, obesity, type 2 diabetes.
- Neurodegenerative disease models.
- DNA repair and genomic stability studies.
- Mitochondrial health and energy metabolism research.
How It Is Dosed in Research Settings
- Intravenous (IV): Research protocols often use 250–1000 mg per infusion, delivered over 1–4 hours.
- Injectable (IM or Subcutaneous): Doses of 50–200 mg daily or several times weekly are studied in experimental models.
- Oral / Sublingual precursors: Compounds such as NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are studied for their ability to raise NAD+ levels, typically in 250–1000 mg daily ranges.
- Cycle length: Protocols vary — from short detox or recovery studies (7–10 days) to longer aging research trials (weeks to months).
- Handling: Supplied as solution or lyophilized powder; requires cold storage and light protection for stability.
Important Considerations
- Regulatory status: NAD+ is not FDA-approved as a therapy. It is available as a supplement precursor (e.g., NR, NMN), but IV and injectable NAD+ remain experimental.
- Evidence base: Growing body of preclinical and early clinical studies supports potential benefits; large-scale human trials are ongoing.
- Safety: Generally well tolerated in research, though IV infusions may cause flushing, nausea, headache, or fatigue. Long-term effects are still under investigation.
Disclaimer
This material is provided for educational purposes only and summarizes published research on NAD+.
It is not medical advice. NAD+ is experimental, not FDA-approved for general therapeutic use, and should not be viewed as a therapy for medical use.
This peptide is for research use only.